Key Takeaway: Nurix is making strides in developing therapies that target a wide range of BTK mutants, which are known to resist traditional inhibitors and other degraders. Their focus on protein degradation aims to provide innovative solutions for cancer and autoimmune diseases. The company emphasizes its commitment to translating scientific insights into effective treatments.
Price reaction · baseline $6.88 (2023-10-05 close) · hit pre-market · clean, no other NRIX news in the window
day 0 close · peak
+3.5%
Market Sentiment Analysis
POSITIVE FACTORS
Nurix is advancing a multi-modal portfolio of therapies.
The research focuses on clinically-relevant BTK mutants.
The therapies aim to outmatch cancer and autoimmune diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What are NX-5948 and NX-2127?
NX-5948 and NX-2127 are therapies developed by Nurix targeting BTK mutants.
What is the significance of BTK mutants?
BTK mutants can resist traditional inhibitors, making them crucial targets for new therapies.
What diseases do these therapies aim to treat?
These therapies aim to treat cancer and autoimmune diseases.
How does Nurix approach therapy development?
Nurix focuses on translating scientific insights into breakthrough therapies.